JR, C., H, A., B, B., M, B., VJ, C., R, L., . . . D, M. (2021). Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(9), e3545. https://doi.org/10.1093/cid/ciaa1169
Chicago Style (17th ed.) CitationJR, Campbell, Al-Jahdali H, Bah B, Belo M, Cook VJ, Long R, Schwartzman K, Trajman A, and Menzies D. "Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium Tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 73, no. 9 (2021): e3545. https://doi.org/10.1093/cid/ciaa1169.
MLA (9th ed.) CitationJR, Campbell, et al. "Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium Tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 73, no. 9, 2021, p. e3545, https://doi.org/10.1093/cid/ciaa1169.
